das ist ein Referenzwert der durchaus zunerzielen ist. Warst du in Canada und hast dir das angeschaut was die machen?
Top-News
Neuester,
zuletzt geles. Beitrag
Antworten | Hot-Stocks-Forum Übersicht
Zurück
Weiter
... 72 73 74 76 77 78 ...
Antworten | Hot-Stocks-Forum Übersicht
Zurück
Weiter ... 72 73 74 76 77 78 ...
ChroMedX!
Beiträge: 3.800
Zugriffe: 900.017 / Heute: 351
Zugriffe: 900.017 / Heute: 351
|
Werbung
Entdecke die beliebtesten ETFs von SPDR
SPDR S&P U.S. Technology Select Sector UCITS ETF
Perf. 12M: +41,91%
SPDR S&P U.S. Communication Serv. Select Sector UCITS ETF Ac
Perf. 12M: +41,85%
SPDR MSCI World Technology UCITS ETF
Perf. 12M: +39,12%
SPDR MSCI World Communication Services UCITS ETF
Perf. 12M: +38,43%
SPDR MSCI Europe Technology UCITS ETF
Perf. 12M: +32,71%
wie kommst du drauf, das sie noch 1-2 Jahre Kohle haben ??
siehe 1578, eher wohl bald gar keine OHNE Wandlungen !!
dich sehr Cobra, denn du sagst wahre Worte .. aber wenn du nicht dabei bist find ich schade und aber wenn es für dich nicht passt Richtig. Hier muss etwas bis März passiert sein und entweder vetraut man oder vertraut man nicht.
www.healthcaremarketing.eu/unternehmen/...rnehmen&nr=50138
www.healthcaremarketing.eu/unternehmen/...rnehmen&nr=48279
m.shortnews.de/Detail/...p;CFID=157920688&CFTOKEN=62818736
Abbott übernimmt I-STAT für 392 Mio. Dollar, Aktie + 18 Prozent
Der amerikanische Pharmakonzern Abbott Laboratories Inc. kündigte am Montag den Kauf der noch verbleibenden Anteile des Blutanalyse-Spezialisten I-STAT Corp. für insgesamt 392 Mio. Dollar an.
Abbott bietet den Aktionären von I-STAT 15,35 Dollar je Aktie in bar. Durch die Übernahme will Abbott sein Portfolio im Bereich Medizin-Diagnostik verstärken.
Der amerikanische Pharmakonzern Abbott Laboratories Inc. kündigte am Montag den Kauf der noch verbleibenden Anteile des Blutanalyse-Spezialisten I-STAT Corp. für insgesamt 392 Mio. Dollar an.
Abbott bietet den Aktionären von I-STAT 15,35 Dollar je Aktie in bar. Durch die Übernahme will Abbott sein Portfolio im Bereich Medizin-Diagnostik verstärken.
kann so wie beim I-stat laufen. Wenn der Hemopalm das kann was er verspricht bekommen wir genau so einen deal! Jetzt sag mir Cobra ehrlich was du davon hälst bitte
ziehst einfach ein Quervergleich...
so einfach ist es aber nicht, dafür müssen ja fast alle Parameter gleich sein, was ich nicht
glaube..
wir werden es sehen, gegönnt sei es euch ;-)
scheint ja Konkurrenz zu geben, siehe deine Links, also wer braucht das Hemopalm
wenn Abbot und Siemens mit ihrer sehr professionellen DD sich andere ausgesucht haben zum Übernehmen, die Sache hat zwei Seiten Zaubr, oder ??
Zitat
Peter Koerte, President Point of Care Diagnostics bei Siemens Healthineers: "Als einer der Marktführer im Segment Blutgas-Analyse wird die Akquisition der Epoc-Produktlinie es uns ermöglichen, die richtige Lösung für das richtige Anwendungsumfeld anbieten zu können, alles von einem Partner. Die Epoc-Produktlinie wird sich nahtlos in unser digitales Ökosystem integrieren, das Kunden dann die breiteste verfügbare Lösung im Markt anbietet." Siemens Healthineers verfüge für die Blutgasuntersuchung künftig über ein Sortiment von der Einmalanalyse mit dem mobilen Device bis zur Multi-Analyse am Diagnostik-Arbeitsplatz.
recht aber eine erstaunliche ähnlichkeit! :D Danke dir ich würd mich freuen dich auch weiterhin zu lesen. wenn..
ich fehlt dir die Information das die Geräte entscheidende Dinge nicht können die der Hemo Palm verspricht. Sonsz wäre alles hier witzlos.. Chromedx will mit dem HP ein völlig neuartiges gerät bringen, moment bitze
RJ: ChroMedX initially engaged DxEconomix to explore the economic value of the HemoPalm and assist in identifying the ideal path to market for the technology. After I conducted my preliminary due diligence I brought Thomas and another colleague with experience with ISTAT and Epocalto take a closer look and it was then that we determined this was an opportunity that we had to take a more active role in.
TS: “Wow, this is a game changer!” Pretty much instantly, we saw it as the next or 3rd generation of POCT blood gas analyzers with real potential to further improve management of critically ill patients. It represented the next logical step in the evolution of diagnosis in this area, and it was the response to a well-recognized, unmet need in the blood gas domain. Specifically, it is, the combination of blood gas analyses and co-oximetry on the same device, using the same patient blood sample for both!
TS: “Wow, this is a game changer!” Pretty much instantly, we saw it as the next or 3rd generation of POCT blood gas analyzers with real potential to further improve management of critically ill patients. It represented the next logical step in the evolution of diagnosis in this area, and it was the response to a well-recognized, unmet need in the blood gas domain. Specifically, it is, the combination of blood gas analyses and co-oximetry on the same device, using the same patient blood sample for both!
doch einfach mega spannend! Die beste story seit Jahren..
niemandem zum Kauf überreden. Jeder dem das hier nicht zusagt den kann ich bestens verstehen. Für mich ist das ein Spiel, dass ich zwar gewinnen will, aber mein Leben hängt nicht davon ab. Ich hab auch oft an der Seitenlinie gestanden und mir meinen Teil gedacht.. Ich fordere niemanden zum Handeln auf ich teile lediglich meine Sichtweise dar.
"Ich kann zwar die Bahn der Gestirne auf Zentimeter und Sekunde berechnen, aber nicht, wohin eine verrückte Menge einen Börsenkurs treiben kann."
-Sir Isaac Newton
"Ich kann zwar die Bahn der Gestirne auf Zentimeter und Sekunde berechnen, aber nicht, wohin eine verrückte Menge einen Börsenkurs treiben kann."
-Sir Isaac Newton
ChroMedX Corp. Expands Executive Team;Lahav Gil Appointed CEO and Director
January 05, 2018 – ChroMedX Corp. (the “Company”) (CSE: CHX, OTC: CHXIF, Frankfurt: EIY2), developer of the HemoPalm Handheld Blood Analyzer System, is pleased to announce the appointments of MedTech visionary Lahav Gil as Chief Executive Officer and W. Clark Kent as President of the Company. Both have also been appointed to the Company’s board of directors.
Mr. Gil joins ChroMedX as the founder and former CEO of the innovative Toronto-based medical device industrial design and productization organization, Kangaroo Group (ISO 13485). Lahav founded the company in 2003 and evolved it into a full-spectrum outsourcing platform for Medical Device innovation, engineering, design, productization, RA submissions and contract manufacturing, contributing to many product launches in the Canadian and international MedTech industry. Kangaroo was acquired by full service medical device design company Starfish Medical in April of 2017.
“Lahav’s achievements speak for themselves but his energy, vision and passion for design and development is something truly remarkable.” said Gerard Edwards, Executive Chairman, ChroMedX Corp. “This appointment is an exciting milestone in a plan that the board of directors have been working on for quite sometime. We are proud to appoint Lahav as CEO and welcome him to the board of directors.”
Lahav is well known in the community for his strong team building abilities and emphasis on innovation culture, as well as his track record as a MedTech entrepreneur, design-driven innovator, and business leader.
“With the HemoPalm, ChroMedx is well positioned to bring a remarkable and critically needed product to market.” said Lahav Gil, CEO & Director, ChroMedX Corp. “Successful commercializing of a medical device relies on a deep and profound understanding of the problems that you are trying to solve at all levels of the product and business offering. Critically understanding the requirements of all the stakeholders including those leading to a strategic acquisition are key to this success, as well as designing for frictionless adoption models, a superior user experience, and a robust supply chain. It is essential to build a team and corporate culture that intuitively and strategically understands these concepts and loves working together on meaningful innovation and I am very excited to join ChroMedX and lead this process.”
W. Clark Kent has been appointed President and joined the ChroMedX board of directors. Clark is a capital markets professional with extensive experience leading corporate development and finance initiatives in the life sciences, technology and natural resource industries. For over a decade he has advised emerging companies on strategic planning, finance and recruitment in the North American and international marketplace.
“As a long-time supporter and consultant Clark has been instrumental in the advancement of ChroMedX and the HemoPalm technology.” said Gerard Edwards, Executive Chairman, ChroMedX Corp. “Clark has most recently been responsible for the Company’s partnership with DxEconomix and introduction to Lahav Gil. We are very pleased to now welcome him as a director and fulltime member of the team as ChroMedX President.”
With the appointments of Mr. Gil and Mr. Kent, Ash Kaushal will step down from his President, CEO and Director roles. Mr. Kaushal joined the Company as President and CEO in July 2016 after serving as a key consultant since the Company’s inception. The ChroMedX board of directors would like to thank Ash for his contributions and leadership in 2017. Mr. Kaushal will continue to work with the Company on a consulting basis.
With these appointments ChroMedX has increased its board to 6 directors. Further information on the Company’s executive team, board of directors and key advisors can be found at www.chromedx.com
About Lahav Gil
Lahav is the founder and former CEO of the Toronto based Kangaroo Group, which he built into a national brand and recently sold to Starfish Medical of Vancouver Island. He is passionate about meaning, loves Innovation Culture, Values-Based Leadership, transparency & awareness.
Lahav has deep experience in Medtech product development and business. He has founded/co-founded 6 companies and has accompanied many Canadian start-ups on their journey from napkin to launch, critically contributing to their investability, clinical and market readiness. He has contributed to over 200 technology product launches and to game-changing innovations for companies such as: IMRIS, FIO, fSona, Cellaegis, XOR, Ultrasonix, Exact Imaging, Sciex, and others.
For almost 3 decades, he has been involved with tech-innovation, entrepreneurship, and start-up companies, starting in Israel’s bustling innovation climate of the 80's. During the late 90's Lahav integrated into the Canadian innovation scene, leading Industrial Design projects and corporate-wide iD strategy for Creo/Kodak in Vancouver, where he first got a taste of the crucial role of culture in business. In 2003 he founded Kangaroo Design, which he evolved into the Kangaroo Group (ISO 13485), a full-spectrum outsourcing platform for Medical Devices innovation, engineering, design, productization, RA submissions and contract manufacturing.
Under his leadership, Kangaroo supplied services, infrastructure, and incubation partnerships to Canadian Medtech startups and entrepreneurs for over 15 years. During this time, Lahav’s main focus was building Kangaroo as a platform alongside spin-ins, spin-outs & incubation-investments.
Recent News
ChroMedX most recently announced the signing of a definitive agreement with diagnostics marketing experts DxEconomix to lead initiatives relating to potential high-value transactions. Further information can be found on the Company’s website.
Website
Investors and individuals interested in keeping abreast of latest news and updates can subscribe on the Home and News pages on the Company's website at www.ChroMedX.com
About ChroMedX Corp.
ChroMedX Corp. is a medical technology company focused on the development of novel medical devices for in vitro diagnostics and point-of-care testing. The devices are protected by the Company’s issued and pending patents, dealing with blood collection, analysis and plasma/serum processing.
The HemoPalm Handheld Blood Analyzer System is the only handheld blood analysis technology which combines Blood Gases & Electrolytes with full CO-oximetry. Currently this combination is not available on any of the handheld analyzers on the market. Existing technologies require users to purchase a second device to carry out the CO-oximetry. The Company’s technology has the advantage of being able to offer a single handheld blood analyzer that provides all the required tests for Blood Gases & Electrolytes, with full CO-oximetry and bilirubin. Another competitive advantage of the HemoPalm system will be its ability to draw capillary blood directly from a pin-prick site into the cartridge, providing an alternative to arterial blood. Drawing arterial blood is painful and can cause nerve damage. CO-oximetry is the measurement of five different hemoglobin species in blood.
The global market for Blood Gases & Electrolytes was estimated to be 1.5 Billion $US in 2015 and is projected to reach over 1.8 Billion by 2020.
January 05, 2018 – ChroMedX Corp. (the “Company”) (CSE: CHX, OTC: CHXIF, Frankfurt: EIY2), developer of the HemoPalm Handheld Blood Analyzer System, is pleased to announce the appointments of MedTech visionary Lahav Gil as Chief Executive Officer and W. Clark Kent as President of the Company. Both have also been appointed to the Company’s board of directors.
Mr. Gil joins ChroMedX as the founder and former CEO of the innovative Toronto-based medical device industrial design and productization organization, Kangaroo Group (ISO 13485). Lahav founded the company in 2003 and evolved it into a full-spectrum outsourcing platform for Medical Device innovation, engineering, design, productization, RA submissions and contract manufacturing, contributing to many product launches in the Canadian and international MedTech industry. Kangaroo was acquired by full service medical device design company Starfish Medical in April of 2017.
“Lahav’s achievements speak for themselves but his energy, vision and passion for design and development is something truly remarkable.” said Gerard Edwards, Executive Chairman, ChroMedX Corp. “This appointment is an exciting milestone in a plan that the board of directors have been working on for quite sometime. We are proud to appoint Lahav as CEO and welcome him to the board of directors.”
Lahav is well known in the community for his strong team building abilities and emphasis on innovation culture, as well as his track record as a MedTech entrepreneur, design-driven innovator, and business leader.
“With the HemoPalm, ChroMedx is well positioned to bring a remarkable and critically needed product to market.” said Lahav Gil, CEO & Director, ChroMedX Corp. “Successful commercializing of a medical device relies on a deep and profound understanding of the problems that you are trying to solve at all levels of the product and business offering. Critically understanding the requirements of all the stakeholders including those leading to a strategic acquisition are key to this success, as well as designing for frictionless adoption models, a superior user experience, and a robust supply chain. It is essential to build a team and corporate culture that intuitively and strategically understands these concepts and loves working together on meaningful innovation and I am very excited to join ChroMedX and lead this process.”
W. Clark Kent has been appointed President and joined the ChroMedX board of directors. Clark is a capital markets professional with extensive experience leading corporate development and finance initiatives in the life sciences, technology and natural resource industries. For over a decade he has advised emerging companies on strategic planning, finance and recruitment in the North American and international marketplace.
“As a long-time supporter and consultant Clark has been instrumental in the advancement of ChroMedX and the HemoPalm technology.” said Gerard Edwards, Executive Chairman, ChroMedX Corp. “Clark has most recently been responsible for the Company’s partnership with DxEconomix and introduction to Lahav Gil. We are very pleased to now welcome him as a director and fulltime member of the team as ChroMedX President.”
With the appointments of Mr. Gil and Mr. Kent, Ash Kaushal will step down from his President, CEO and Director roles. Mr. Kaushal joined the Company as President and CEO in July 2016 after serving as a key consultant since the Company’s inception. The ChroMedX board of directors would like to thank Ash for his contributions and leadership in 2017. Mr. Kaushal will continue to work with the Company on a consulting basis.
With these appointments ChroMedX has increased its board to 6 directors. Further information on the Company’s executive team, board of directors and key advisors can be found at www.chromedx.com
About Lahav Gil
Lahav is the founder and former CEO of the Toronto based Kangaroo Group, which he built into a national brand and recently sold to Starfish Medical of Vancouver Island. He is passionate about meaning, loves Innovation Culture, Values-Based Leadership, transparency & awareness.
Lahav has deep experience in Medtech product development and business. He has founded/co-founded 6 companies and has accompanied many Canadian start-ups on their journey from napkin to launch, critically contributing to their investability, clinical and market readiness. He has contributed to over 200 technology product launches and to game-changing innovations for companies such as: IMRIS, FIO, fSona, Cellaegis, XOR, Ultrasonix, Exact Imaging, Sciex, and others.
For almost 3 decades, he has been involved with tech-innovation, entrepreneurship, and start-up companies, starting in Israel’s bustling innovation climate of the 80's. During the late 90's Lahav integrated into the Canadian innovation scene, leading Industrial Design projects and corporate-wide iD strategy for Creo/Kodak in Vancouver, where he first got a taste of the crucial role of culture in business. In 2003 he founded Kangaroo Design, which he evolved into the Kangaroo Group (ISO 13485), a full-spectrum outsourcing platform for Medical Devices innovation, engineering, design, productization, RA submissions and contract manufacturing.
Under his leadership, Kangaroo supplied services, infrastructure, and incubation partnerships to Canadian Medtech startups and entrepreneurs for over 15 years. During this time, Lahav’s main focus was building Kangaroo as a platform alongside spin-ins, spin-outs & incubation-investments.
Recent News
ChroMedX most recently announced the signing of a definitive agreement with diagnostics marketing experts DxEconomix to lead initiatives relating to potential high-value transactions. Further information can be found on the Company’s website.
Website
Investors and individuals interested in keeping abreast of latest news and updates can subscribe on the Home and News pages on the Company's website at www.ChroMedX.com
About ChroMedX Corp.
ChroMedX Corp. is a medical technology company focused on the development of novel medical devices for in vitro diagnostics and point-of-care testing. The devices are protected by the Company’s issued and pending patents, dealing with blood collection, analysis and plasma/serum processing.
The HemoPalm Handheld Blood Analyzer System is the only handheld blood analysis technology which combines Blood Gases & Electrolytes with full CO-oximetry. Currently this combination is not available on any of the handheld analyzers on the market. Existing technologies require users to purchase a second device to carry out the CO-oximetry. The Company’s technology has the advantage of being able to offer a single handheld blood analyzer that provides all the required tests for Blood Gases & Electrolytes, with full CO-oximetry and bilirubin. Another competitive advantage of the HemoPalm system will be its ability to draw capillary blood directly from a pin-prick site into the cartridge, providing an alternative to arterial blood. Drawing arterial blood is painful and can cause nerve damage. CO-oximetry is the measurement of five different hemoglobin species in blood.
The global market for Blood Gases & Electrolytes was estimated to be 1.5 Billion $US in 2015 and is projected to reach over 1.8 Billion by 2020.
Du solltest mal an deinem Verteiler arbeiten.
Die Info ist 2 Tage alt. Und wenn du mal bischen nach oben scrollst, da steht schon alles drin.
Die Info ist 2 Tage alt. Und wenn du mal bischen nach oben scrollst, da steht schon alles drin.
Wir sehen relativ bald 2€, die Frage stellt sich nur dann wer nimmt Sie und sagt vielen Dank und wer bleibt dabei. Die aktuell tausende Bitcoin Millionäre bleiben dabei und am Ende bleiben eine Hand voll übrig. Muss jeder selbst wissen ob er traded oder investiert und wo sein Zielpreis liegt und zwar jetzt sonst geht man wie die Bitcoin Freunde am Ende leer aus. Just for fun wird das Spiel auf Dauer sehr teuer.
Nur meine Meinung
Nur meine Meinung
den Neuen HemoPalm wollen alle die den neuen Goldstandart in der Oximetrie-
messung in einem Gerät haben wollen!
Wenn man die beiden Geräte aus der Epoc Linie und den HemoPalm vergleicht stellt
man fest das das eine (Epoc) eine A- Klasse ist und das andere Gerät (HemoP.) eine
E- Klasse !
Also wirklich nicht vergleichbar!
Das erstere hat nur einen Biosensor und braucht venöses Blut ( dauert länger und die Gewinnung ist
aufwendiger und darf nur von Ausgebildeten Ärzten angewandt werden) = TEURER!
volle Oximetrie nur über Zweitgerät!
HemoPalm Gerät= Kapillarblut, auch von eingewiesenen Laien bedienbar, Biosensor und Opt.Sensor =volle Oximetrie, schnellere Ergebnisse, Zeit und Kostenersparnis.
Ich habe hier den Eindruck das das Gerät von Epoc zwar zu Siemens passt
Allere aber froh ist sie das "veralterte" Gerät los geworden sind, man könnte sich ja jetzt bei CMX
wieder neu und aktuell eindecken, der nicht genannte Kaufpreis der von Siemens nach
Allere geflossen ist würde sicherlich einen Teil der Kosten decken die eine Übernahme von CMX
mit sich bringt.
Gruß Starkoch
PS Alles nur meine Meinung und keine Aufforderung zum Handeln mit dieser Aktie.
messung in einem Gerät haben wollen!
Wenn man die beiden Geräte aus der Epoc Linie und den HemoPalm vergleicht stellt
man fest das das eine (Epoc) eine A- Klasse ist und das andere Gerät (HemoP.) eine
E- Klasse !
Also wirklich nicht vergleichbar!
Das erstere hat nur einen Biosensor und braucht venöses Blut ( dauert länger und die Gewinnung ist
aufwendiger und darf nur von Ausgebildeten Ärzten angewandt werden) = TEURER!
volle Oximetrie nur über Zweitgerät!
HemoPalm Gerät= Kapillarblut, auch von eingewiesenen Laien bedienbar, Biosensor und Opt.Sensor =volle Oximetrie, schnellere Ergebnisse, Zeit und Kostenersparnis.
Ich habe hier den Eindruck das das Gerät von Epoc zwar zu Siemens passt
Allere aber froh ist sie das "veralterte" Gerät los geworden sind, man könnte sich ja jetzt bei CMX
wieder neu und aktuell eindecken, der nicht genannte Kaufpreis der von Siemens nach
Allere geflossen ist würde sicherlich einen Teil der Kosten decken die eine Übernahme von CMX
mit sich bringt.
Gruß Starkoch
PS Alles nur meine Meinung und keine Aufforderung zum Handeln mit dieser Aktie.
zusammengefasst Koch! du bist einfach der Mann für die Technik. Wenn du magst lade ich doch zum Nachbarthread herzlichst ein. Gute Männer braucht das Land!
hat auch mal wieder was über chrom
"Breaking News – Med-Tech-Papst übernimmt das Steuer – Kursexplosion am Montag"
"Breaking News – Med-Tech-Papst übernimmt das Steuer – Kursexplosion am Montag"
kein Autor geworden ist ^J^)
Also aufgepasst Morgen explosiontag.
Also aufgepasst Morgen explosiontag.
www.bullvestorbb.com/...tech-pabst-uebernimmt-das-steuer/amp/
|
Neueste Beiträge aus dem Scryb Forum
| Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
| 19 | Scryb-Relay Medical-Chromedx | PapaSchlumpf41 | PapaSchlumpf41 | 29.06.23 01:01 | ||
5 | 3.799 | ChroMedX! | iwanooze | Ebi52 | 08.01.22 12:55 | |
| 22 | Der Deutsche Investmentreport emfiehlt | buran | sweetmandy | 25.04.21 02:59 | ||
| 20 | nicht handelbar | tigermike | Chadoner | 24.04.18 20:06 |
